EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Elexacaftor–tezacaftor–ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis

Anna C Zemke iD, Yasmin Hilliam, Amanda L Stapleton, Adam J Kimple, Jennifer L Goralski, Amber D Shaffer iD, Joseph M Pilewski, Brent A Senior iD, Stella E Lee, Vaughn S Cooper

International Forum of Allergy & Rhinology · 2024

DOI: 10.1002/alr.23288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Forum of Allergy & Rhinology, 2024. Verfasst von Anna C Zemke und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Sinusitis, Rhinitis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIEHS NIH HHS, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic rhinosinusitis (CRS) is common in individuals with cystic fibrosis (CF) and is marked by chronic inflammation and episodes of infection that negatively impact quality of life. Several studies have shown that elexacaftor–tezacaftor–ivacaftor (ETI) improves symptoms and examination findings in CF‐CRS. The current study determines the effect of ETI on the sinonasal microbiota in CF.

Methods

Sinonasal samples were collected under endoscopic visualization before and after starting ETI. Samples were subjected to 16S amplicon sequencing and sequences were processed with the QIIME2 pipeline with subsequent analysis using the vegan R‐package.

Results

Twenty‐nine individual baseline samples and 23 sample pairs pre‐/post‐ETI were available. At baseline, the cohort had samples dominated by Staphylococcus , and alpha diversity was lower than that of a published reference set of individuals without sinonasal disease. Individuals with prior sinus surgery had lower alpha diversity as measured by Shannon Index, Observed Richness, and Faith's phylogenetic diversity Index. Beta diversity differed between individuals with and without allergic rhinitis, with higher Staphylococcus abundance in those with allergic rhinitis. No change in alpha or beta diversity was seen after a median of 9 months on ETI. With ETI, the Pseudomonas genus and the genus containing Burkholderia decreased in samples containing these taxa at baseline. Pseudomonas abundance decreased with treatment as measured by qPCR. Core sinonasal microbiome members Staphylococcus , Corynebacterium , and Streptococcus were unchanged, while Moraxella increased with ETI.

Conclusions

Treatment with ETI leads to a reduction in Pseudomonas abundance within the sinonasal microbiome of individuals with Pseudomonas at baseline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsSinusitisRhinitisMicrobiotaIndolesQuinolonesParanasal SinusesDrug CombinationsBenzodioxolesPyrrolidinesHumansFemaleMaleAdultYoung AdultPseudomonasChronic DiseaseAdolescentPyrazolesPyrrolesPyridines

Stichwörter der Autor:innen

chronic rhinosinusitiselexacaftor–ivacaftor–tezacaftormicrobiomemicrobiota

Substanzen

AminophenolsIndolesivacaftorQuinolonesDrug CombinationsBenzodioxoleselexacaftortezacaftorPyrazolesPyrroles

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • Department of Otolaryngology-Head & Neck Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Otolaryngology-Head & Neck Surgery, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Division of Pulmonary Diseases & CCM, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Anna C Zemke, Amber D Shaffer, Brent A Senior

Förderung

  • NHLBI NIH HHS
  • NIEHS NIH HHS
  • Cystic Fibrosis Foundation

Zitieren

APA

Zemke, A. C., Hilliam, Y., Stapleton, A. L., Kimple, A. J., Goralski, J. L., Shaffer, A. D., Pilewski, J. M., Senior, B. A., Lee, S. E., & Cooper, V. S. (2024). Elexacaftor–tezacaftor–ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23288

Vancouver

Zemke AC, Hilliam Y, Stapleton AL, Kimple AJ, Goralski JL, Shaffer AD, et al. Elexacaftor–tezacaftor–ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis. International Forum of Allergy & Rhinology. 2024. doi:10.1002/alr.23288

BibTeX
@article{Zemke2024,
  author = {Zemke, Anna C and Hilliam, Yasmin and Stapleton, Amanda L and Kimple, Adam J and Goralski, Jennifer L and Shaffer, Amber D and Pilewski, Joseph M and Senior, Brent A and Lee, Stella E and Cooper, Vaughn S},
  title = {Elexacaftor–tezacaftor–ivacaftor decreases pseudomonas abundance in the sinonasal microbiome in cystic fibrosis},
  journal = {International Forum of Allergy & Rhinology},
  year = {2024},
  doi = {10.1002/alr.23288}
}
Kostenlos starten →